Biologics in Rheumatology - JAK and TNF alpha

Speciality: Rheumatology


Speaker:

Prof ( Dr ) Ved Chaturvedi | MD, DM, Sr Consultant Rheumatology & Immunology

DR P D RATH | MD,FACR,FRCP(Edin),FRCP(Glasgow) FNIMS,FRCM,GCPR(AUS), Diploma MSK USG(UCAM SPAIN) Director & Head Of Deptt. Rheumatology

Dr. Nilesh Nolkha | MD, DM (Clinical Immunology & Rheumatology), Consultant Rheumatologist

Description:

A warm welcome to all the medical professionals in this memorable scientific session of JAKi and TNFi in rheumatological disorder.

The primary subject of discussion in this webinar is immunological responses in rheumatic diseases and the role of TNF alpha inhibitors and JAK inhibitors in rheumatological disorders. You will get a broader knowledge of the above mentioned topic through the real world evidence provided in this session. 

The speakers Prof ( Dr ) Ved Chaturvedi, DR P D RATH, and Dr. Nilesh Nolkha has immense knowledge and experience in the field of rheumatology. In this webinar they have discussed how the TNF alpha inhibitors and JAK inhibitors play a key role in altering immune responses in rheumatological diseases. 
 
TNF alpha inhibitor and JAK inhibitor drugs help in controlling inflammation in different conditions such as rheumatoid arthritis (RA), psoriatic arthritis, juvenile idiopathic arthritis, inflammatory bowel disease (Crohn's and ulcerative colitis), ankylosing spondylitis, and psoriasis. 

Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
 


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer during young adulthood carries long-term mental toll, study finds

2.

In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.

3.

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

4.

Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.

5.

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot